DK1554301T3 - Dengue-vaccine med en fælles udeladelse af 30 nukleotider i Dengue-typerne 1's og 2's3'UTR - Google Patents

Dengue-vaccine med en fælles udeladelse af 30 nukleotider i Dengue-typerne 1's og 2's3'UTR

Info

Publication number
DK1554301T3
DK1554301T3 DK03724319.3T DK03724319T DK1554301T3 DK 1554301 T3 DK1554301 T3 DK 1554301T3 DK 03724319 T DK03724319 T DK 03724319T DK 1554301 T3 DK1554301 T3 DK 1554301T3
Authority
DK
Denmark
Prior art keywords
dengue
utr
nucleotides
types
vaccine
Prior art date
Application number
DK03724319.3T
Other languages
English (en)
Inventor
Joseph Blaney
Stephen S Whitehead
Brian R Murphy
Lewis Markoff
Barry Falgout
Kathryn Hanley
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of DK1554301T3 publication Critical patent/DK1554301T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
DK03724319.3T 2002-05-03 2003-04-25 Dengue-vaccine med en fælles udeladelse af 30 nukleotider i Dengue-typerne 1's og 2's3'UTR DK1554301T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37786002P 2002-05-03 2002-05-03
US43650002P 2002-12-23 2002-12-23
PCT/US2003/013279 WO2003092592A2 (en) 2002-05-03 2003-04-25 Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4

Publications (1)

Publication Number Publication Date
DK1554301T3 true DK1554301T3 (da) 2011-01-24

Family

ID=29406814

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03724319.3T DK1554301T3 (da) 2002-05-03 2003-04-25 Dengue-vaccine med en fælles udeladelse af 30 nukleotider i Dengue-typerne 1's og 2's3'UTR
DK10177735.7T DK2338508T3 (da) 2002-05-03 2003-04-25 rDEN3/4delta 30(ME), rDEN2/4delta30(ME) eller rDEN1/4delta30(ME) rekombinant kimær Dengue-virus indeholdende en 30 nukleotiddeletion (delta30) i en sektion af den 3'-utranslaterede region af Dengue type 4 genom, hvor 30-nukleotiddeletionen svarer til TL2-hårnålestrukturen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK10177735.7T DK2338508T3 (da) 2002-05-03 2003-04-25 rDEN3/4delta 30(ME), rDEN2/4delta30(ME) eller rDEN1/4delta30(ME) rekombinant kimær Dengue-virus indeholdende en 30 nukleotiddeletion (delta30) i en sektion af den 3'-utranslaterede region af Dengue type 4 genom, hvor 30-nukleotiddeletionen svarer til TL2-hårnålestrukturen

Country Status (15)

Country Link
US (7) US7517531B2 (da)
EP (5) EP3763382A1 (da)
JP (1) JP4977811B2 (da)
AT (1) ATE481982T1 (da)
BR (1) BRPI0309631B1 (da)
CA (1) CA2483653C (da)
CY (1) CY1120558T1 (da)
DE (1) DE60334310D1 (da)
DK (2) DK1554301T3 (da)
ES (2) ES2355719T3 (da)
HU (1) HUE037330T2 (da)
PT (2) PT1554301E (da)
SI (2) SI2338508T1 (da)
TR (1) TR201806655T4 (da)
WO (1) WO2003092592A2 (da)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3763382A1 (en) * 2002-05-03 2021-01-13 The Government of The United States of America, as represented by The Secretary, Department of Health and Human Services Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1, 2, 3, and 4, or antigenic chimeric dengue viruses 1, 2, 3, and 4
EP1874346B1 (en) 2005-04-24 2014-06-25 Sanofi Pasteur Biologics, LLC Recombinant flavivirus vaccines
JP4549224B2 (ja) * 2005-04-25 2010-09-22 出光ユニテック株式会社 透明ポリプロピレン系樹脂シートの製造方法、透明ポリプロピレン系樹脂シート、及び成形品、並びに透明ポリプロピレン系樹脂シートからなる成形品の白化防止方法、及び温度判別方法
WO2006134433A1 (en) * 2005-06-17 2006-12-21 Sanofi Pasteur Dengue serotype 1 attenuated strain
AU2006257621B2 (en) * 2005-06-17 2011-08-11 Centers For Disease Control And Prevention Dengue serotype 2 attenuated strain
US8017754B2 (en) 2005-07-22 2011-09-13 Research Development Foundation Attenuated virus strains and uses thereof
AU2016219680B2 (en) * 2006-08-15 2018-08-09 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Development of dengue virus vaccine components
AU2013263788B2 (en) * 2006-08-15 2016-05-26 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Development of dengue virus vaccine components
SI2589602T1 (sl) 2006-08-15 2016-08-31 The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health Office of Technology Transfer Razvoj sestavin cepiva proti virusu denge
JP5620146B2 (ja) 2009-05-22 2014-11-05 三星ディスプレイ株式會社Ｓａｍｓｕｎｇ Ｄｉｓｐｌａｙ Ｃｏ．，Ｌｔｄ． 薄膜蒸着装置
TWI475124B (zh) 2009-05-22 2015-03-01 Samsung Display Co Ltd 薄膜沉積設備
KR101117719B1 (ko) * 2009-06-24 2012-03-08 삼성모바일디스플레이주식회사 박막 증착 장치
JP5328726B2 (ja) 2009-08-25 2013-10-30 三星ディスプレイ株式會社 薄膜蒸着装置及びこれを利用した有機発光ディスプレイ装置の製造方法
JP5677785B2 (ja) 2009-08-27 2015-02-25 三星ディスプレイ株式會社Ｓａｍｓｕｎｇ Ｄｉｓｐｌａｙ Ｃｏ．，Ｌｔｄ． 薄膜蒸着装置及びこれを利用した有機発光表示装置の製造方法
JP6057460B2 (ja) * 2009-08-31 2017-01-11 ジェン−プローブ・インコーポレーテッド デングウイルスアッセイ
US8876975B2 (en) 2009-10-19 2014-11-04 Samsung Display Co., Ltd. Thin film deposition apparatus
KR101084184B1 (ko) 2010-01-11 2011-11-17 삼성모바일디스플레이주식회사 박막 증착 장치
KR101174875B1 (ko) 2010-01-14 2012-08-17 삼성디스플레이 주식회사 박막 증착 장치, 이를 이용한 유기 발광 디스플레이 장치의 제조방법 및 이에 따라 제조된 유기 발광 디스플레이 장치
KR101193186B1 (ko) 2010-02-01 2012-10-19 삼성디스플레이 주식회사 박막 증착 장치, 이를 이용한 유기 발광 디스플레이 장치의 제조방법 및 이에 따라 제조된 유기 발광 디스플레이 장치
KR101156441B1 (ko) 2010-03-11 2012-06-18 삼성모바일디스플레이주식회사 박막 증착 장치
KR101202348B1 (ko) 2010-04-06 2012-11-16 삼성디스플레이 주식회사 박막 증착 장치 및 이를 이용한 유기 발광 표시 장치의 제조 방법
US8894458B2 (en) 2010-04-28 2014-11-25 Samsung Display Co., Ltd. Thin film deposition apparatus, method of manufacturing organic light-emitting display device by using the apparatus, and organic light-emitting display device manufactured by using the method
IT1400574B1 (it) 2010-05-06 2013-06-14 Freni Brembo Spa Dispositivo di frenatura a disco per veicoli
US8685649B2 (en) * 2010-06-10 2014-04-01 The United States Of America As Represented By The Secretary Of The Navy RT-LAMP assay for the detection of pan-serotype dengue virus
KR101223723B1 (ko) 2010-07-07 2013-01-18 삼성디스플레이 주식회사 박막 증착 장치, 이를 이용한 유기 발광 디스플레이 장치의 제조방법 및 이에 따라 제조된 유기 발광 디스플레이 장치
EP2621525A4 (en) * 2010-10-01 2015-01-14 Univ Rochester Flavivirus DOMAIN III VACCINE
KR101738531B1 (ko) 2010-10-22 2017-05-23 삼성디스플레이 주식회사 유기 발광 디스플레이 장치의 제조 방법 및 이에 따라 제조된 유기 발광 디스플레이 장치
KR101723506B1 (ko) 2010-10-22 2017-04-19 삼성디스플레이 주식회사 유기층 증착 장치 및 이를 이용한 유기 발광 디스플레이 장치의 제조 방법
KR20120045865A (ko) 2010-11-01 2012-05-09 삼성모바일디스플레이주식회사 유기층 증착 장치
US20120294889A1 (en) * 2010-11-12 2012-11-22 Paxvax, Inc. Chimeric Flavivirus Vaccines
KR20120065789A (ko) 2010-12-13 2012-06-21 삼성모바일디스플레이주식회사 유기층 증착 장치
KR101760897B1 (ko) 2011-01-12 2017-07-25 삼성디스플레이 주식회사 증착원 및 이를 구비하는 유기막 증착 장치
KR101852517B1 (ko) 2011-05-25 2018-04-27 삼성디스플레이 주식회사 유기층 증착 장치 및 이를 이용한 유기 발광 디스플레이 장치의 제조 방법
KR101840654B1 (ko) 2011-05-25 2018-03-22 삼성디스플레이 주식회사 유기층 증착 장치 및 이를 이용한 유기 발광 디스플레이 장치의 제조 방법
KR101857249B1 (ko) 2011-05-27 2018-05-14 삼성디스플레이 주식회사 패터닝 슬릿 시트 어셈블리, 유기막 증착 장치, 유기 발광 표시장치제조 방법 및 유기 발광 표시 장치
KR20130004830A (ko) 2011-07-04 2013-01-14 삼성디스플레이 주식회사 유기층 증착 장치 및 이를 이용한 유기 발광 표시 장치의 제조 방법
KR101826068B1 (ko) 2011-07-04 2018-02-07 삼성디스플레이 주식회사 유기층 증착 장치
KR102015872B1 (ko) 2012-06-22 2019-10-22 삼성디스플레이 주식회사 유기층 증착 장치, 이를 이용한 유기 발광 디스플레이 장치의 제조 방법 및 이에 따라 제조된 유기 발광 디스플레이 장치
US8895028B2 (en) 2012-07-20 2014-11-25 Arbovax, Inc. Methods and compositions for dengue virus 3 (DV3) infectious clone
CN104812408A (zh) * 2012-07-24 2015-07-29 赛诺菲巴斯德有限公司 用于防止登革热病毒感染的疫苗组合物
KR102081284B1 (ko) 2013-04-18 2020-02-26 삼성디스플레이 주식회사 증착장치, 이를 이용한 유기발광 디스플레이 장치 제조 방법 및 유기발광 디스플레이 장치
US9861692B2 (en) 2013-06-21 2018-01-09 Merck Sharp & Dohme Corp. Dengue virus vaccine compositions and methods of use thereof
NO340722B1 (no) * 2014-06-27 2017-06-06 Norwegian Institute For Agricultural & Environmental Res Transgene planter som uttrykker et rekombinant tetravalent kimært denguevirusantigen for å fremstille effektive vaksiner avledet derfra, samt transgent plastid, plantecelle og frø, rekombinant DNA molekyl, vektor, fremgangsmåter for fremstilling og anvendelse derav
MX2017008342A (es) 2014-12-22 2017-10-24 Merck Sharp & Dohme Composiciones de vacuna para el virus del dengue y metodos de uso de las mismas.
US10004795B2 (en) * 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
US11285202B2 (en) * 2016-01-26 2022-03-29 University Of South Carolina Polymer-protein core-shell particles as effective vaccine delivery vehicles and treatments methods using the same
KR20180127397A (ko) 2016-03-11 2018-11-28 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 생약독화된 지카 바이러스 백신
EP3442571A1 (en) * 2016-04-13 2019-02-20 Takeda Vaccines, Inc. Compositions and methods of vaccination against dengue virus in children and young adults
WO2018129160A1 (en) 2017-01-06 2018-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Live attenuated flavivirus vaccines and methods of using and making same
JOP20200140A1 (ar) 2017-12-07 2022-10-30 Merck Sharp & Dohme صيغ لتركيبات لقاح فيروس حُمى الضنك
EP3846848A4 (en) * 2018-09-04 2022-07-06 The Board of Regents of the University of Texas System DNA PLASMID INITIATED LIVE VACCINES FOR PLUS-POLARITY SINGLE STRAND RNA VIRUS
WO2021173597A1 (en) * 2020-02-28 2021-09-02 Merck Sharp & Dohme Corp. Dengue serotype specific rt-pcr multiplex assay
WO2023161715A1 (en) * 2022-02-22 2023-08-31 Futr Bio Ltda. Next generation mrna vaccines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002539821A (ja) * 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 脊椎動物細胞へのウイルスの適用
EP1159969A1 (fr) * 2000-05-30 2001-12-05 Aventis Pasteur Vaccine composition
CA3114957C (en) * 2001-05-22 2022-02-08 Stephen S. Whitehead Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
EP3763382A1 (en) * 2002-05-03 2021-01-13 The Government of The United States of America, as represented by The Secretary, Department of Health and Human Services Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1, 2, 3, and 4, or antigenic chimeric dengue viruses 1, 2, 3, and 4
SI2589602T1 (sl) * 2006-08-15 2016-08-31 The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health Office of Technology Transfer Razvoj sestavin cepiva proti virusu denge

Also Published As

Publication number Publication date
PT1554301E (pt) 2010-12-28
BRPI0309631B1 (pt) 2021-07-20
US8075903B2 (en) 2011-12-13
BRPI0309631A2 (pt) 2016-11-01
EP1554301A4 (en) 2006-11-08
SI2338508T1 (en) 2018-07-31
AU2003231185A1 (en) 2003-11-17
BRPI0309631A8 (pt) 2018-09-25
EP1554301A2 (en) 2005-07-20
JP2005532044A (ja) 2005-10-27
SI1554301T1 (sl) 2011-01-31
WO2003092592A2 (en) 2003-11-13
USRE46631E1 (en) 2017-12-12
EP2338508A1 (en) 2011-06-29
EP3205352A1 (en) 2017-08-16
EP2338508B1 (en) 2018-02-14
ATE481982T1 (de) 2010-10-15
US11753627B2 (en) 2023-09-12
EP2319532A1 (en) 2011-05-11
US20070009552A1 (en) 2007-01-11
DK2338508T3 (da) 2018-05-28
EP1554301B1 (en) 2010-09-22
DE60334310D1 (de) 2010-11-04
CA2483653C (en) 2014-10-28
PT2338508T (pt) 2018-05-16
US20180010099A1 (en) 2018-01-11
US10837003B2 (en) 2020-11-17
CY1120558T1 (el) 2019-07-10
ES2677348T3 (es) 2018-08-01
US7517531B2 (en) 2009-04-14
US9783787B2 (en) 2017-10-10
JP4977811B2 (ja) 2012-07-18
HUE037330T2 (hu) 2018-08-28
USRE46641E1 (en) 2017-12-19
US20090258036A1 (en) 2009-10-15
US20200392469A1 (en) 2020-12-17
WO2003092592A3 (en) 2005-05-19
CA2483653A1 (en) 2003-11-13
TR201806655T4 (tr) 2018-06-21
ES2355719T3 (es) 2011-03-30
US20130011433A1 (en) 2013-01-10
EP3763382A1 (en) 2021-01-13

Similar Documents

Publication Publication Date Title
DK1554301T3 (da) Dengue-vaccine med en fælles udeladelse af 30 nukleotider i Dengue-typerne 1's og 2's3'UTR
TW200745120A (en) Indolobenzazepine HCV NS5B inhibitors
WO2009039248A8 (en) Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection
DE602005027747D1 (de) Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen
EA201201356A1 (ru) Композиция для лечения респираторных синцитиальных вирусов
ZA200007403B (en) Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals.
ATE297757T1 (de) Chimäre impfstoffe gegen flaviviren
ATE197607T1 (de) Chimäre und/oder wachstumgehemmte flaviviren
MX2007009628A (es) Virus de acido ribonucleico en replicacion como vacunas.
EP2270162A3 (en) Conserved HBV and HCV sequences useful for gene silencing
DE60217465D1 (de) Nukleosidderivate als inhibitoren von rna-abhängiger rna viralpolymerase
EA200700243A1 (ru) Способы лечения гепатита с
WO2007025043A3 (en) Seven-membered ring nucleosides
ATE452900T1 (de) Impfstoff gegen das west-nile-virus
EP2092078A4 (en) THE REPLICATION OF THE HEPATITIS C VIRUS REPLICON INHIBITING NUCLEASERESISTENT RNA APTAMER
DK1425404T3 (da) Vaccinia-MVA-E3L-mutanter og anvendelse deraf
WO2002072803A3 (en) Subgenomic replicons of the flavivirus dengue
WO2010107742A3 (en) Methods and compositions of treating a flaviviridae family viral infection
DE60040219D1 (de) Infektiöses cdna klon des gb-virus b und dessen verwendungen
DK1411128T3 (da) Rekombinante, virale vektorer indeholdende genet for den humane urogenaseplasminogenaktivator og deres anvendelse ved behandling af hepatitisk fibrose
WO2007035530A3 (en) Ancestral dengue virus envelope protein sequence
WO1999057284A3 (en) Attenuated influenza viruses
NZ511168A (en) Recombinant CELO virus and CELO virus DNA
CY1117369T1 (el) Εμβολιο για τον δαγγειο πυρετο που περιεχει μια κοινη 30 νουκλεοτιδιων διαγραφη στην 3'-utr των τυπων 1 και 2 ιου του δαγγειου πυρετου
DK1254663T3 (da) Antivirusmiddel